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Abstract
Background: Malaria and Tuberculosis (TB) are important causes of morbidity and mortality in Africa. Malaria
prevention reduces mortality among HIV patients, pregnant women and children, but its role in TB patients is not
clear. In the TB National Reference Center in Guinea-Bissau, admitted patients are in severe clinical conditions and
mortality during the rainy season is high. We performed a three-step malaria prevention program to reduce
mortality in TB patients during the rainy season.
Methods: Since 2005 Permethrin treated bed nets were given to every patient. Since 2006 environmental
prevention with permethrin derivates was performed both indoor and outdoor during the rainy season. In 2007
cotrimoxazole prophylaxis was added during the rainy season. Care was without charge; health education on
malaria prevention was performed weekly. Primary outcomes were death, discharge, drop-out.
Results: 427, 346, 549 patients were admitted in 2005, 2006, 2007, respectively. Mortality dropped from 26.46% in
2005 to 18.76% in 2007 (p-value 0.003), due to the significant reduction in rainy season mortality (death/discharge
ratio: 0.79, 0.55 and 0.26 in 2005, 2006 and 2007 respectively; p-value 0.001) while dry season mortality remained
constant (0.39, 0.37 and 0.32; p-value 0.647). Costs of malaria prevention were limited: 2€/person. No drop-outs
were observed. Health education attendance was 96-99%.
Conclusions: Malaria prevention in African tertiary care hospitals seems feasible with limited costs. Vector control,
personal protection and cotrimoxazole prophylaxis seem to reduce mortality in severely ill TB patients. Prospective
randomized trials are needed to confirm our findings in similar settings.
Trial registration number: Current Controlled Trials: ISRCTN83944306
Background
Malaria and Tuberculosis are important causes of mor-
bidity and mortality in Africa [1] and are among the
main reasons of hospital admission and in-hospital mor-
tality [2-5]. During the rainy season, malaria burden
increases [6-8] in many African countries, peaking mor-
bidity and mortality. Regardless of HIV status, malaria
infection affects severely ill TB patients who are already
compromised by malnutrition, deprived immunity or
disseminated disease [6,9,10]. In fact, in pulmonary TB
there is a transient systemic immunosuppression due to
over expression of transforming growth factor beta and
interleukin-10 [11]. Interactions between TB and
malaria have been demonstrated both in vitro and in
vivo: Plasmodium Falciparum modulates Mycobacterium
Tuberculosis infection [12] and malaria has been shown
to exacerbate mycobacterial infection [13]. The reasons
for this are not completely explored but seem to involve
parasite-parasite interaction and host-parasite interac-
tion [12-14]: malaria causes a further depression in
immunity through a qualitative and quantitative defect
in T lymphocytes, mainly the CD8+ that are necessary
for anti-mycobacterial response, and through a deregula-
tion of the cytokine cascade. Moreover, the respiratory
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children (due to metabolic acidosis) and adults (due to
pulmonary edema and Acute Respiratory Distress Syn-
drome) [15], can worsen the respiratory effort related to
TB. Therefore, given the multiple interactions between
malaria and TB and the mutual effect in increasing mor-
tality [1,5,6], new strategies of integrated management
should be investigated, especially during malaria peak
transmission seasons. The identification of efficacious
and low cost methods for reducing malaria in TB
patients could largely improve clinical outcome and
public health strategies optimizing the use of current
limited resources.
Malaria prevention can be performed at various levels
and several measures are proven to be quite effective in
different groups of patients [16-20].
TB Reference Hospitals can be the sites to test inte-
grated models of malaria prevention for severely ill
patients due to the fact that those who are in poor con-
ditions are generally admitted for at least the intensive
phase of TB treatment (two months).
In the Hospital Raoul Follereau (HRF), National Refer-
ence Hospital for Tuberculosis and Lung Disease in Bis-
sau, Guinea-Bissau, mortality during 2004 rainy season
reached peaks of 60% in admitted patients. According to
the clinical reports made by the hospital’s physicians,
high fever with Plasmodium Falciparum positive blood
film was the main reason of death. In order to reduce
mortality during the rainy season in admitted TB
patients, since January 2005 we performed a malaria
prevention program in the hospital. Our hypothesis was
that the successive combination of personal protection,
vector control and cotrimoxazole prophylaxis could be
progressively more effective in reducing mortality in
severely affected TB patients, who are admitted for long
periods of time. Several other drugs with a potential bet-
ter efficacy are used for malaria prophylaxis, but in the
peculiar context of TB Units where almost half of the
patients is HIV+ [1,21,22], the use of cotrimoxazole
would potentially integrate the interventions and facili-
tate the long-term administration by the health care
workers.
Methods
Setting
Guinea-Bissau is located in the West African Atlantic
C o a s t .T h e r ea r et w oc l i m a t i cs e a s o n s :ar a i n ys e a s o n
from July to October and a dry season from November
to June. Malaria is endemic with a peak transmission
during the rainy season. The Hospital Raoul Follereau
(HRF) is the National Reference Hospital for Tuberculo-
sis and Lung Disease in Bissau, capital of Guinea-Bissau.
According to the National Guidelines for TB, TB
patients in poor clinical conditions or with severe
disease (i.e important wasting or respiratory distress) are
admitted after referral from regional hospitals or from
TB health centers across the entire country.
After being destroyed during the 1998-1999 civil war,
the hospital was rebuilt and reopened to the public in
2004. The hospital is a 2500 sqm structure surrounded
by a 7500 sqm grass garden (Figure 1). The whole
facility includes an in-patient service (three wards:
men, women and children), an outpatient service, a
laboratory, two X-Ray Units, a pharmacy, a service
area (kitchen, laundry, ironing) and two cafeterias.
From 2003 to 2008 the hospital policy was to perform
clinical evaluation, diagnostic tests, treatment and
nutritional support without charge to all admitted
patients.
Study outline and Malaria Prevention
Malaria prevention was performed through a three-step
intervention. A Permethrin treated bed net was given to
every patient upon admission since 2005 and during all
the three years of the intervention; bed nets were
retreated every 30-45 days.
Environmental disinfection was performed monthly
with Permethrin based products by appropriately trained
hospital staff according to manufactory’s instructions
during the rainy season of 2006 and 2007; spraying was
conducted both outdoor (with Microsin) and indoor
(with Petrin L) on doors and window frames. The only
difference was that in 2006 environmental outdoor and
indoor disinfection was repeated monthly from July 15th
to October 30th while in 2007, due to increased avail-
ability of the products, it was repeated monthly from
June 1st to October 30th.
Figure 1 Hospital Raoul Follereau from the satellite
http://www.googlemaps.com.
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famethoxazole 400 mg tablet was given to every patient
admitted from July 1st to October 30th only in 2007.
The study was approved by the Hospital Board. All
patients gave informed oral consent and all patients
benefited from the interventions.
Diagnosis of TB and Malaria and standard treatment
As part of routine clinical evaluation, patients who were
admitted with a suspect of TB, received a three sample
sputum analysis, a thorax X-Ray, a complete blood
count, a biochemistry analysis and a malaria thick film.
Ziehl-Neelsen’s sputum staining technique was used and
patients were considered smear positive if acid fast
bacilli were shown on at least two samples. Smear nega-
tive patients were considered to have TB according to
the physician’s evaluation of chest X-Ray and clinical
condition. Additional analyses were performed if neces-
sary, based on physician’s judgment.
HIV testing and Antiretroviral treatment were offered
free of charge to patients admitted from July to August,
in November and in March of every year; alternatively,
due to the limited availability of free reagents and drugs,
patients were advised to undergo HIV testing in other
health facilities and return back the result.
A clinical episode of malaria was defined as an axillary
temperature ≥37.5°C together with the presence of
malaria parasitemia at any density.
The hospital treatment protocols for TB, Malaria,
HIV/AIDS and other diseases were the same in 2005,
2006, 2007. TB was treated according to the National
Guidelines, with a four drug regimen for two months
(rifampicin, isoniazid, ethambutol and pyrazinamide) fol-
lowed by two drugs for the following six months (isonia-
zid and ethambutol); five drugs were used in case of
relapsed TB (streptomycin, rifampicin, isoniazid, etham-
butol and pyrazinamide). Chloroquine was administered
as standard treatment in case of uncomplicated malaria,
while severe malaria was treated with iv Quinine,
according to the National Program against Malaria in
Guinea-Bissau. Other medications were given on a clini-
cal basis. Nutritional support was similarly implemented
over the three years and included three main meals and
two snacks given daily to all patients.
Compliance to treatment (TB drugs, cotrimoxazole
and other drugs) was assured by direct observation of
drug intake by the nurses.
Health education on TB, malaria, HIV, water-borne
diseases and personal hygiene was part of the hospital
care standards: every week an appropriately trained
nurse performed health education lessons to in-patients
and the number of participants was recorded. The
importance of malaria prevention and bed net use was
particularly stressed during the lessons.
Outcomes
Primary outcomes were death or discharge from hospi-
tal. Secondary outcomes were drop-outs (defined as
voluntary discharge from hospital before recovery
against physician’s advice and/or treatment abandon-
ment) and percentage of attendance of health education
classes.
Data collection
Personal and clinical information were transferred from
patient’s individual charts to Microsoft Access 2000
(Microsoft Corporation, Seattle, WA, USA). Hospital
registries were used to cross-check diagnosis and admis-
sion-discharge dates. Pearson’s chi-square test was used
to compare variables within groups. p-values<0 . 0 5w e r e
considered statistically significant.
Results
A total of 427, 346 and 549 patients were admitted in
2005, 2006 and 2007, respectively. Major baseline char-
acteristics -gender, symptoms on admission and diagno-
sis- were similar in the thr e eg r o u p so fp a t i e n t sa s
shown in Table 1. The majority of patients were adults
ranging from 15 to 59 years, even if the +60 years group
was less numerous in 2006. TB diagnosis was confirmed
Table 1 Patient’s clinical characteristics
2005 2006 2007 p-value
Admissions (N°) 427 346 549
N° % N° % N° %
Gender
M 232 54.3% 203 58.8% 310 56.4% 0.480
F 195 45.7% 143 41.2% 239 43.6%
Age (years)
14- 53 12.4% 55 15.9% 92 16.8%
15-59 325 76.1% 268 77.5% 395 71.9% 0.043
60+ 49 11.5% 23 6.6% 62 11.3%
Symptoms on
admission
Cough 392 92% 317 91.6% 499 90.8%
Fever 366 85.7% 294 84.9% 486 88.5% 0.866
Chest pain 319 74.7% 252 72.8% 428 78%
Weight loss 289 67.7% 248 71.6% 390 71%
Diagnosis
TB 306 71.7% 239 69.1% 390 71%
Pulmonary TB
Smear+
157 120 195
Pulmonary TB
Smear-
107 99 150 0.387
Extra Pulmonary
TB
32 20 31
Lung Disease No TB 94 22% 83 23.9% 110 20%
Other 27 6.3% 24 7% 49 9%
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being more frequent. HIV prevalence was similar (43%,
45% and 48% in 2005, 2006 and 2007, respectively) as
well as the proportion of patients receiving Antiretro-
viral Therapy every year (78%, 75%, 79% in 2005, 2006
and 2007 respectively). Between 64-69.8% were HIV1,
20-23.5% were HIV2 and 10.2-11.7% HIV1/2.
Mean Length of Stay (LOS) during the three years was
78 days (77, 87, 70 days in 2005, 2006, 2007
respectively).
Outcomes
A significant reduction in mortality was observed from
2005 to 2007 (26.46% vs 18.76%, p-value 0.003). Detailed
outcomes for rainy season and dry season are presented
in Table 2 and Table 3 respectively. The main determi-
nant of the annual mortality reduction was shown to be
the drop of rainy season mortality. In fact, the death/dis-
charge ratio significantly decreased during the rainy sea-
son (0.79, 0.55 and 0.26 in 2005, 2006 and 2007
respectively; p-value 0.001) while remained fairly stable
during the dry season (0.39, 0.37 and 0.32 in 2005, 2006
and 2007 respectively; p-value 0.647).
Deaths occurring during the first week of admission and
therefore not influenced by malaria prophylaxis, were 41%,
28% and 47% during the rainy season in 2005, 2006 and
2007 respectively (p-value 0.178). Death/Discharge ratio
calculated considering only deaths occurring after the first
week, were again highly significant (p-value 0.001): 0.51,
0.40 and 0.14 in 2005, 2006 and 2007 respectively.
None of the patients abandoned treatment or asked to
be discharged before completing the two months of TB
intensive phase treatment or before clinical recovery.
Every health education class was attended by 96-99%
of the admitted patients.
A reduction in Plasmodium Falciparum positive blood
films was observed from the period August-November
2005 to August-November 2006 and 2007 (23.65% vs.
15.7% vs. 8.4% respectively, p-value 0.001) but the
results were not registered on a regular basis.
Costs
The overall cost of the entire malaria prevention pro-
gram in 2007 was estimated to be €1050 (USD 1402).
This figure includes: re-treatment of bed nets every
45 days along the year, outdoor and indoor disinfection
performed during the rainy season and cotrimoxazole
prophylaxis during the rainy season, with a mean cost of
2€/patient. Additional purchases were the spray pump
and the facial mask that can be used for several years
(€500 or USD 668). Bed nets were donated to the hospi-
tal by the Global Fund Malaria initiative over the three
years.
Discussion
Our study suggests that malaria prevention is feasible in
African hospital settings and can involve both environ-
ment-focused and patient-focused interventions. Perme-
thrin treated bed nets, outdoor and indoor environment
disinfection and cotrimoxazole prophylaxis seem to have
a cumulative protective effect on survival in severely ill
TB patients.
Malaria and TB are a heavy burden to African health
systems; the arrangement of integrated approaches of
management with limited resources is still a challenge
[1,5,6]. Seasonal variation in malaria related mortality
[7,23] is well known in West-African countries and sea-
sonal interventions have been effective in Gambia,
Guinea-Bissau and Senegal [7,18,24]. Guinea-Bissau has
one of the highest incidences of TB in the world [1] and
malaria is an important death determinant in the coun-
try, since 45% of registered deaths are caused by malaria
[25,26]. The majority of malaria related deaths occurs
during the rainy season [25,26]. Therefore, it seems rea-
sonable to target malaria prevention strategies to the
rainy season.
Table 2 Rainy season (July-October) outcomes of hospitalization in 2005, 2006 and 2007
Outcomes 2005 2006 2007 p-value
Admissions
Total (n°) 158 130 173
Mean per month 39,5 32,5 43,25
Deaths
Total (n°) 60 44 36
Mean per month 15 11 9
Discharges
Total (n°) 76 80 137
Mean per month 19 20 34.25
Mortality (Death/Admission)% 37.9 33.8 20.8 0.0032
(CI 95%:30.4%-45.54%) (CI 95%:25.72%-41.98%) (CI 95%:14.76%-26.86%)
Death/Discharge ratio 0.78 0.55 0.26 0.001
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benefit, even if environmental disinfection and cotri-
moxazole prophylaxis seemed to be the most effective.
Permethrin treated bed nets reduce malaria infection
offering both a mechanical and chemical barrier to mos-
quito bites and are efficacious in children and adults
[16-18]. Insecticide treated bed nets and cotrimoxazole
prophylaxis have shown to reduce malaria infection in
HIV+ adults [19,27], children [28] and pregnant women
[20,29,30]. Environmental disinfection, with indoor and
outdoor spraying, is a useful tool to fight malaria in several
countries [21,31,32]. A limit of vector control strategies
has been the difficulty to deliver the reagents on time (i.e.
at the beginning of the rainy season) to households spread
in large areas and to perform re-treatment on schedule
[31]. A hospital-based intervention overcomes these pro-
blems since patients are admitted in the same place for
several months. Hospital outdoor and indoor spraying
leads to a parasite intensity/density reduction and there-
fore can be an additional strategy to reduce the malaria
burden in severely ill TB patients [20,32].
Cotrimoxazole prophylaxis administered to HIV+
patients has reduced malaria episodes in their HIV-sero-
negative household members [33] and was also effica-
cious in Mali with 99% prophylactic efficacy against
malaria infection and disease in children [34]. Limited
information are available on the role of cotrimoxazole
for malaria prophylaxis in HIV-seronegative TB patients,
even if once daily cotrimoxazole has reduced overall
mortality in TB patients regardless of HIV status in
S o u t hA f r i c a[ 2 1 ]a n da l s om o r t a l i t ya n dm a l a r i ai n f e c -
tion in HIV+ TB patients in Abidjan [22].
The benefit of cotrimoxazo l ei no u rs t u d ym a yh a v e
been enhanced by the potential reduction of gastroin-
testinal illnesses, sepsis [34,35], pneumonia and toxo-
plasmosis [36,37], often leading causes of death in
immunocompromised patients. These factors have not
been directly investigated by our study and a prospective
randomized study may address the specific correlations.
Nevertheless, the poor clinical conditions of in-patients
with severe or disseminated TB infection, usually mal-
nourished, might justify the use of cotrimoxazole for
short periods of time, regardless their HIV status.
Concerns regarding the induction of high resistance
to cotrimoxazole in non-typhoid salmonella bacteria or
in other opportunistic pathogens and the implications
on the potential benefits of co-trimoxazole prophylaxis
in HIV-infected individuals have been raised; however,
the size of this phenomenon has not yet been proven
to compromise the short and mid-term effectiveness of
cotrimoxazole prophylaxis [38]. Therefore, there are no
compelling reasons to believe that our approach could
be of any harm from a public health perspective. The
rapid evolution of antifolate resistance observed in
malaria in sub-Saharan African countries -where
bacterial resistance to cotrimoxazole is higher and
cross-resistance between cotrimoxazole and sulfadox-
ine-pyrimethamine (SP) may impair SP efficacy for
malaria treatment- raises questions about the durability
of this strategy. A careful resistance analysis to evalu-
ate the emergence of resistance to the drug should be
performed to tailor malaria prevention.
The overall cost of vector control, personal protection
and prophylaxis in our setting was really limited: only
€2/patient allow a net gain in survival with a reduction
of death/discharge ratio from 0.76 to 0.26. Surely, there
is a higher cost of malaria in-patient care compared to
prevention [5]. Malaria’s economic impact is enormous
[6] and the high direct cost for treating illness justifies
efforts to improve coverage of preventive measures.
Malaria preventive strategies targeting high risk groups
-as severely ill TB patients- in high burden seasons -as
the rainy season- could reduce diagnostic and treatment
direct cost for families (where user fees are applied) and
health services (where health care is provided without
charge) while reducing mortality.
Table 3 Dry season (November-June) outcomes of hospitalization in 2005, 2006, 2007
Outcomes 2005 2006 2007 p-value
Admissions
Total (n°) 269 216 376
Mean per month 33.62 27 47
Deaths
Total (n°) 53 51 67
Mean per month 6.62 6,37 8,37
Discharges
Total (n°) 137 136 208
Mean per month 17.12 17 26
Mortality (Death/Admission)% 19.7 23.6 17.8 0.385
(CI 95%: 14.95%-24.45%) (CI 95%:17.95%-29.27%) (CI 95%:13.95%-21.69%)
Death/Discharge ratio 0.38 0.37 0.32 0.647
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HIV prevalence were fairly constant along the three
years of the intervention. Mortality during the first week
of admission, and therefore not influenced by malaria
prophylaxis, was also always above 28% suggesting that
late presentation to the health center was a major factor
for in-hospital death. Unfortunately, it is a common pro-
blem in TB facilities across Africa [39,40]. There was no
effect on mortality by age in our group of patients, even
if susceptibility to severe malaria is affected by age, but
this could be due to the relative small proportion of
children in our group.
No drop-outs were observed. This is a remarkable
data considering the high drop-out rates in many TB
programs in Africa [1]. The free access to diagnosis and
to all components of treatment (pharmacological and
nutritional) that was offered by the hospital in those
years was surely a major determinant for good compli-
ance. Repeated health education (once a week) per-
formed by trained personnel was also attractive for
patients (96-99% of admitted patients attended each
class) and reinforced sleeping under bed nets as well
other healthy behaviors.
Our study has several limits. Firstly, it is an observa-
tional study and therefore it doesn’th a v et h ep o w e ro fa
randomized study. Nevertheless, even if it doesn’tc o m -
pare the three different strategies in a randomized fash-
ion, the three-step intervention testes them subsequently
and suggests the additive benefit of each successive one
(death/discharge ratio dropped from 0.79 to 0.55 to 0.26).
Secondly, malaria was not evaluated as a secondary out-
come and therefore there is no direct demonstration that
the reduction in mortality was due to the reduction in
the number of both malaria episodes and malaria related
mortality. Even so, all treatment protocols and main clin-
ical characteristic of patient population remained fairly
unchanged along the three years, and the only modifying
interventions were related to malaria prevention.
A reduction in positive blood films was indeed observed
from the period August-November 2005 to August-
November 2006 and 2007 (23.65% vs. 15.7% vs. 8.4%
respectively, p-value 0.001), and even if the results were
not registered on a regular basis and therefore are not
completely reliable, they contribute to the hypothesis
that malaria reduction was a determinant of reduced
mortality. It is unlikely that patients died partly as
a result of ineffective treatment for their malaria because
chloroquine resistance is scarce in the country pro-
bably due to the higher chloroquine dosages routinely
used [41].
Conclusion
In conclusion, our prospective observational study sug-
gests that malaria vector control, personal protection
a n dc o t r i m o x a z o l ep r o p h y l a x i sc a nb eas a f ea n dl o w
cost measure to reduce in-hospital mortality in TB
patients admitted in reference centers due to their poor
clinical status and/or disseminated disease. Free care
and health education have a role in reducing drop-outs
in TB and malaria hospital-based programs. Prospective
randomized trials are neededt oc o n f i r mo u rf i n d i n g s
and understand the role of cotrimoxazole in reducing
overall morality and malaria related mortality in TB
patients.
Acknowledgements
The Authors thank the Health Ministry of Guinea-Bissau and the Programa
Nacional de Luta contra a Tuberculose for the support in TB drug and
diagnostic reagents; USAID and the Global Fund for the support in
mosquito nets, drugs and food to admitted patients; the Community of
Sant’Egidio for rebuilding the hospital after the 1998-1999 civil war and for
co-ordinating and sustaining the hospital’s activity allowing all patients to
receive free care.
Author details
1Clinic of Pediatric Hematology-Oncology, Department of Pediatrics,
University of Padova, Padova, Italy.
2National Reference Hospital for
Tuberculosis and Lung Disease, Bissau, Guinea- Bissau.
3Infectious Disease
Unit, Department of Pediatrics, University of Padova, Padova, Italy.
4University
of Padova, Padova, Italy.
5Department of Public Health and Cell Biology “Tor
Vergata” University, Rome, Italy.
Authors’ contributions
CR: designed the study, interpreted the data and wrote the manuscript; PM:
interpreted the data and reviewed the manuscript; BF: designed the study
and collected the data; VCS: performed the study and collected the data;
ALA: performed the study and collected the data; VF: performed the study
and collected the data; TS: performed statistical analysis; GC: reviewed the
manuscript; RF: designed the study, interpreted the data and reviewed the
manuscript.
All authors read and approved the final manuscript
Competing interests
The authors declare that they have no competing interests.
Received: 31 August 2010 Accepted: 2 March 2011
Published: 2 March 2011
References
1. World Health Organization: Global Tuberculosis control 2009: Epidemiology,
strategy, financing. [http://www.who.int/tb/publications/global_report/
2009/pdf/full_report.pdf], Last accessed 26 March 2010.
2. Soumaré M, Seydi M, Diop SA, Ba TA, Ndour CT, Dieng Y, Diop BM, Sow PS:
The place of malaria in an infectious disease department in Dakar,
Senegal. Med Trop (Mars) 2008, 68:485-90.
3. Petit PL, van Ginneken JK: Analysis of hospital records in four African
countries, 1975-1990, with emphasis on infectious diseases. J Trop Med
Hyg. 1995, 98:217-27.
4. Dgedge M, Novoa A, Macassa G, Sacarlal J, Black J, Michaud C, Cliff J: The
burden of disease in Maputo City, Mozambique: registered and
autopsied deaths in 1994. Bull World Health Organ. 2001, 79:546-52.
5. Hongoro C, McPake B: Hospital costs of high-burden diseases: malaria
and pulmonary tuberculosis in a high HIV prevalence context in
Zimbabwe. Trop Med Int Health. 2003, 8:242-50.
6. Russell S: The economic burden of illness for households in developing
countries: a review of studies focusing on malaria, tuberculosis, and
human immunodeficiency virus/acquired immunodeficiency syndrome.
Am J Trop Med Hyg 2004, 71(2 Suppl):147-55.
7. Zachariah R, Spielmann MP, Harries AD, Salaniponi FM: Moderate to severe
malnutrition in patients with tuberculosis is a risk factor associated with
early death. Trans R Soc Trop Med Hyg. 2002, 96:291-4.
Colombatti et al. BMC Infectious Diseases 2011, 11:57
http://www.biomedcentral.com/1471-2334/11/57
Page 6 of 78. van Lettow M, Fawzi WW, Semba RD: Triple trouble: the role of
malnutrition in tuberculosis and human immunodeficiency virus co-
infection. Nutr Rev 2003, 61:81-90.
9. Anya SE: Seasonal variation in the risk and causes of maternal death in
the Gambia: malaria appears to be an important factor. Am J Trop Med
Hyg. 2004, 70:510-3.
10. Romagosa C, Ordi J, Saute F, Quintó L, Machungo F, Ismail MR, Carrilho C,
Osman N, Alonso PL, Menendez C: Seasonal variations in maternal
mortality in Maputo, Mozambique: the role of malaria. Trop Med Int
Health. 2007, 12:62-7.
11. Ellner JJ: Immunoregulation in TB: observations and implications. Clin
Transl Sci. 2010, 3:23-8.
12. Scott CP, Kumar N, Bishai WR, Manabe YC: Short report: modulation of
Mycobacterium tuberculosis infection by Plasmodium in the murine
model. Am J Trop Med Hyg. 2004, 70:144-8.
13. Hawkes M, Li X, Crockett M, Diassiti A, Conrad Liles W, Liu J, Kain KC:
Malaria exacerbates experimental mycobacterial infection in vitro and in
vivo. Microbes Infect 2010, 12:864-74.
14. Enwere GC, Ota MO, Obaro SK: The host response in malaria and
depression of defence against tuberculosis. Ann Trop Med Parasitol. 1999,
93:669-78.
15. Parry E, Godfrey R, Mabey D, Gill Geoffrey: Malaria in Principles of
Medicine in Africa. Cambridge University Press; 2004.
16. ter Kuile FO, Terlouw DJ, Phillips-Howard PA, Hawley WA, Friedman JF,
Kolczak MS, Kariuki SK, Shi YP, Kwena AM, Vulule JM, Nahlen BL: Impact of
permethrin-treated bed nets on malaria and all-cause morbidity in
young children in an area of intense perennial malaria transmission in
western Kenya: cross-sectional survey. Am J Trop Med Hyg 2003, 68(4
Suppl):100-7.
17. Lindblade KA, Eisele TP, Gimnig JE, Alaii JA, Odhiambo F, ter Kuile FO,
Hawley WA, Wannemuehler KA, Phillips-Howard PA, Rosen DH, Nahlen BL,
Terlouw DJ, Adazu K, Vulule JM, Slutsker L: Sustainability of reductions in
malaria transmission and infant mortality in western Kenya with use of
insecticide-treated bednets: 4 to 6 years of follow-up. JAMA. 2004,
291:2571-80.
18. Jaenson TG, Gomes MJ, Barreto dos Santos RC, Petrarca V, Fortini D, Evora J,
Crato J: Control of endophagic Anopheles mosquitoes and human
malaria in Guinea Bissau, West Africa by permethrin-treated bed nets.
Trans R Soc Trop Med Hyg. 1994, 88:620-4.
19. Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, Weidle P,
Lule J, Coutinho A, Solberg P: Effect of co-trimoxazole prophylaxis,
antiretroviral therapy, and insecticide-treated bednets on the frequency
of malaria in HIV-1-infected adults in Uganda: a prospective cohort
study. Lancet. 2006, 367:1256-61.
20. Mabaso ML, Sharp B, Lengeler C: Historical review of malarial control in
southern African with emphasis on the use of indoor residual house-
spraying. Trop Med Int Health. 2004, 9:846-56.
21. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF:
Effectiveness of cotrimoxazole prophylaxis on mortality in adults with
tuberculosis in rural South Africa. AIDS. 2005, 19:163-8.
22. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C,
Djomand G, Ackah A, Domoua K, Kadio A, Yapi A, Combe P, Tossou O,
Roels TH, Lackritz EM, Coulibaly D, De Cock KM, Coulibaly IM, Greenberg AE:
Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease
morbidity and mortality in HIV-1-infected patients with tuberculosis in
Abidjan, Côte d’Ivoire: a randomised controlled trial. Lancet 1999,
353:1469-75, Erratum in: Lancet 1999 Jun;353:2078.
23. Etard JF, Kodio B, Ronsmans C: Seasonal variation in direct obstetric
mortality in rural Senegal: role of malaria? Am J Trop Med Hyg 2003,
68:503-4.
24. Cissé B, Sokhna C, Boulanger D, Milet J, Bâel H, Richardson K, Hallett R,
Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G,
Lines J, Greenwood B, Trape JF: Seasonal intermittent preventive
treatment with artesunate and sulfadoxine-pyrimethamine for
prevention of malaria in Senegalese children: a randomised, placebo-
controlled, double-blind trial. Lancet. 2006, 367:659-67.
25. Plan: [http://www.plan-uk.org/wherewework/westafrica/guineabissau/
rollingbackmalaria/], Accessed 10 April 2010.
26. World Health Organization: [http://www.who.int/malaria/publications/
country-profiles/mal2008-guinea-bissau-en.pdf], Accessed 10 April 2010.
27. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, Kaharuza F,
Culver D, Kizito F, Bunnell R, Kigozi A, Nakanjako D, Wafula W, Quick R:
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell
count, and viral load in HIV infection in rural Uganda. Lancet. 2004,
364:1428-34.
28. Kamya MR, Gasasira AF, Achan J, Mebrahtu T, Ruel T, Kekitiinwa A,
Charlebois ED, Rosenthal PJ, Havlir D, Dorsey G: Effects of trimethoprim-
sulfamethoxazole and insecticide-treated bednets on malaria among
HIV-infected Ugandan children. AIDS. 2007, 21:2059-66.
29. Brentlinger PE, Behrens CB, Micek MA: Challenges in the concurrent
management of malaria and HIV in pregnancy in sub-Saharan Africa.
Lancet Infect Dis 2006, 6:100-11.
30. Belay M, Deressa W: Use of insecticide treated nets by pregnant women
and associated factors in a pre-dominantly rural population in northern
Ethiopia. Trop Med Int Health. 2008, 13:1303-13.
31. World Health Organization, Malaria Vector Control and Personal Protection,
Report of WHO Study Group: WHO Technical Report Series 936. Geneva,
Switzerland; 2004 [http://whqlibdoc.who.int/trs/WHO_TRS_936_eng.pdf],
Last accessed 26 March 2010.
32. Protopopoff N, Van Bortel W, Marcotty T, Van Herp M, Maes P, Baza D,
D’Alessandro U, Coosemans M: Spatial targeted vector control is able to
reduce malaria prevalence in the highlands of Burundi. Am J Trop Med
Hyg. 2008, 79:12-8.
33. Malamba SS, Mermin J, Reingold A, Lule JR, Downing R, Ransom R,
Kigozi A, Hunt BM, Hubbard A, Rosenthal PJ, Dorsey G: Effect of
cotrimoxazole prophylaxis taken by human immunodeficiency virus
(HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-
resistant malaria parasites among HIV-uninfected household members.
Am J Trop Med Hyg. 2006, 75:375-80.
34. Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, Cissoko Y, Kone A,
Guindo A, Dicko A, Beavogui AH, Djimde AA, Lyke KE, Diallo DA,
Doumbo OK, Plowe CV: Impact of trimethoprim-sulfamethoxazole
prophylaxis on falciparum malaria infection and disease. J Infect Dis.
2005, 192:1823-9.
35. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A: UNZA-
UCLMS Project LUCOT Collaboration: Role of co-trimoxazole prophylaxis
in reducing mortality in HIV infected adults being treated for
tuberculosis: randomised clinical trial. BMJ 2008, 10:337:a257.
36. Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, Lishimpi K,
Nunn A, Gillespie S, Zumla A, Chintu C, Gibb DM: CHAP Trial Team: Effect
of cotrimoxazole on causes of death, hospital admissions and antibiotic
use in HIV-infected children. AIDS 2007, 21(1):77-84.
37. Baden LR, Katz JT, Franck L, Tsang S, Hall M, Rubin RH, Jarcho J: Successful
toxoplasmosis prophylaxis after orthotopic cardiac transplantation with
trimethoprim-sulfamethoxazole. Transplantation 2003, 75(3):339-43.
38. Zachariah R, Harries AD, Spielmann MP, Arendt V, Nchingula D, Mwenda R,
Courtielle O, Kirpach P, Mwale B, Salaniponi FM: Changes in Escherichia
coli resistance to co-trimoxazole in tuberculosis patients and in relation
to co-trimoxazole prophylaxis in Thyolo, Malawi. Trans R Soc Trop Med
Hyg 2002, 96:202-4.
39. Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM: High early
death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis. 2001,
5:1000-5.
40. Sacks LV, Pendle S: Factors related to in-hospital deaths in patients with
tuberculosis. Arch Intern Med 1998, 158:1916-22.
41. Ursing J, Kofoed PE, Rodrigues A, Rombo L: No seasonal accumulation of
resistant P. falciparum when high-dose chloroquine is used. PLoS One
2009, 4(8):e6866.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/11/57/prepub
doi:10.1186/1471-2334-11-57
Cite this article as: Colombatti et al.: Malaria prevention reduces in-
hospital mortality among severely ill tuberculosis patients: a three-step
intervention in Bissau, Guinea-Bissau. BMC Infectious Diseases 2011 11:57.
Colombatti et al. BMC Infectious Diseases 2011, 11:57
http://www.biomedcentral.com/1471-2334/11/57
Page 7 of 7